Clinical characteristics of 60 patients with NSCLC and 60 controls.

<p>Age is expressed as mean ± SD.</p

Treatment administered to the 60 patients with NSCLC.

<p>(1) Six patients received concomitant radiation therapy (Stage III).</p><p>(2) Six patients received concomitant radiation therapy (Stage III).</p><p>(3) Three patients received concomitant radiation therapy (Stage III).</p

Levels of CECs, MPs and ETG in patients with NSCLC pre- and post treatment with chemotherapy and in controls.

<p>Data are presented as mean±SD. CECs, circulating endothelial cells; MPs, microparticles; ETG,</p><p>endogenous thrombin generation. <i>P</i>1, pre-treatment <i>vs</i> post-treatment; <i>P</i>2, pre-treatment <i>vs</i> control; <i>P</i>3, post-treatment <i>vs</i> control.</p

Kaplan-Meyer analysis of survival.

<p>OS and PFS in patients according to pre-treatment marker levels (compared to 99^th percentile of controls).The upper reference limit levels of parameters were calculated as values higher than the 99th percentile of the control group (healthy subjects) and were set at: CECs = 20 cells/L; MPs = 3278 MP/µL; ETG = 275 mM. CEC, circulating endothelial cells; MPs, microparticles; ETG, endogenous thrombin generation.</p

Kaplan-Meyer analysis of survival.

<p>The upper reference limit was calculated as values of CECs >152 cells/mL (corresponding to the 75^th percentile of the patient group) CECs: circulating endothelial cells.</p